Salipro Biotech Strengthens Intellectual Property Portfolio
Salipro Biotech has made significant strides in expanding its intellectual property portfolio by securing crucial patents in Singapore and Australia. This development fortifies the company’s proprietary Salipro® platform technology, which is aimed at enabling the creation of therapeutics that target challenging drug targets.
Latest Patents Enhance Drug Discovery Programs
Recently, Salipro Biotech AB, a Swedish biotechnology firm dedicated to advancing drug discovery initiatives, proudly announced the granting of patents for its innovative Salipro® platform technology. This cutting-edge technology facilitates the direct isolation and purification of native membrane proteins. Given that these proteins are critical targets for many therapeutic drugs, this patent issuance represents a milestone achievement.
The patents, named "Production of Salipro® Particles" (Australian Patent No. 2020257991; Singaporean Patent No. 11202111111U), detail processes pivotal to the Salipro® platform. These patents not only bolster Salipro Biotech's stature as a key player in drug discovery but also position the company favorably within the competitive landscape, particularly for difficult drug targets such as GPCRs, ion channels, and transporters.
Comments from Leadership
Jens Frauenfeld, CEO of Salipro Biotech, expressed the importance of these developments, stating, "Securing these patents in Singapore and Australia marks a significant step forward in our global IP strategy, as we continue to build a robust patent portfolio that protects our unique technology and supports our commitment to address unmet medical needs with the Salipro® platform." He emphasized that this achievement is crucial for the long-term growth of their operations, strengthening their intellectual property standing across essential market regions, complementing foundational patents previously granted in the US, EU, and other major jurisdictions such as China and Japan.
Collaborative Strategy for Growth
Peter Jahnmatz, Business Development Director at Salipro Biotech, highlighted the significance of collaboration with leading pharmaceutical companies, noting, "These new patents enhance the value proposition for our partners, driving forward the development of next-generation therapeutics against previously inaccessible drug targets." This collaborative focus underscores Salipro Biotech's strategic direction in fostering innovation through partnerships.
About Salipro Biotech
Established as a privately-owned biotech enterprise, Salipro Biotech aims to unlock challenging drug targets for next-generation therapeutic development. With its headquarters in Stockholm, Sweden, the company controls a comprehensive intellectual property portfolio covering Salipro® platform technology vital for stabilizing membrane proteins.
Membrane proteins constitute a majority of drug targets but tend to be unstable and difficult to analyze. The proprietary Salipro® technology enables the stabilization of these proteins in their native states, making them suitable for application in drug discovery initiatives focused on therapeutic antibodies, small molecule drugs, and structure-based drug design.
Salipro Biotech has successfully entered multiple research collaborations with reputable pharmaceutical and biotech enterprises. Through an effective mix of in-house development and strategic partnerships, the company is advancing the discovery of novel pharmaceuticals.
Frequently Asked Questions
What patents has Salipro Biotech recently granted?
Salipro Biotech recently secured patents for its Salipro® platform technology in Singapore and Australia, enhancing its drug discovery capabilities.
What is the significance of the Salipro® platform technology?
The Salipro® platform technology is vital for isolating and purifying native membrane proteins, which are critical targets for many therapeutic drugs.
Who leads Salipro Biotech?
Jens Frauenfeld serves as the CEO of Salipro Biotech, guiding the company's strategic direction and intellectual property efforts.
How does Salipro Biotech support drug discovery?
The company focuses on stabilizing membrane proteins, making them viable for drug discovery related to therapeutic antibodies and small molecule drugs.
What is the company's collaboration strategy?
Salipro Biotech aims to collaborate with leading pharmaceutical companies to enhance the development of next-generation therapeutics.
